NIJMEGEN, Netherlands – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer micro-environment today announces that it has entered into a strategic partnership with Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, to...
Latest News
Nijmegen, Netherlands – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges...
SOUTH SAN FRANCISCO, Calif. — Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg...
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, Texas — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system...
HOUSTON, TX — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in...
HOUSTON, Texas — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric...
Cambridge, England – Scientists have developed a technique to rapidly and reliably detect genetic changes in malaria parasites in Ghana, using just a gaming laptop and portable MinION sequencer from Oxford Nanopore. Researchers from the Wellcome Sanger Institute and University of Ghana were able to demonstrate for the first time...
Pohang, South Korea – A research team consisting of Professor Kyoung-Duck Park and PhD candidates Taeyoung Moon and Huitae Joo, from the Department of Physics at Pohang University of Science and Technology (POSTECH) has engineered “broadband nanogap gold spectroscopic sensor” using a flexible material capable of bending to create a...
Poland will spend over PLN 700 million (EUR 154.8 million) in 2021-2023 to cure rare diseases as a part of the Rare Disease Plan, the health minister has announced on Monday. Currently, the Plan defines 40 specific tasks and deadlines for their implementation, worth over PLN 90 million (EUR 19.8...
PARAMUS, NJ — Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). The...